February 28, 2022
Now available ENJAYMO™
ENJAYMO™ is a classical complement inhibitor indicated to decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD).
Please see the full prescribing information.